Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026));Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

Journal of Hepatology

Volumn 67, Issue 5, 2017, Pages 999-1008

  Bruix, Jordi ^a   Cheng, Ann Lii ^b   Meinhardt, Gerold ^c   Nakajima, Keiko ^c   De Sanctis, Yoriko ^c   Llovet, Josep ^a,d,e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c BAYER CORPORATION   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Hepatocellular carcinoma; Overall survival; Predictive; Prognostic; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; LEUKOCYTE COUNT; LIVER TUMOR; LYMPHOCYTE; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR INVASION;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LEUKOCYTE COUNT; LIVER NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUTROPHILS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 85028033098     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.07.015     Document Type: Erratum

References (46)

1. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013 [cited 2015 November 9]; Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Global Cancer Facts & Figures, 3rd Edition. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-044738.pdf.
3. Bruix, J., Sherman, M., American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
4. Bruix, J., Reig, M., Sherman, M., Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150 (2016), 835–853.
5. Omata, M., Lesmana, L.A., Tateishi, R., Chen, P.J., Lin, S.M., Yoshida, H., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4 (2010), 439–474.
6. European Association for the Study of the Liver–European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
7. Verslype, C., Rosmorduc, O., Rougier, P., ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (2012), vii41–vii48.
8. Forner, A., Gilabert, M., Bruix, J., Raoul, J.L., Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11 (2014), 525–535.
9. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
10. Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
11. Bruix, J., Raoul, J.L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57 (2012), 821–829.
12. Cheng, A.L., Guan, Z., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 48 (2012), 1452–1465.
13. Llovet, J.M., Villanueva, A., Lachenmayer, A., Finn, R.S., Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12 (2015), 408–424.
14. Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.H., Bodoky, G., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase III trial. Lancet 389 (2017), 56–66.
15. Ozenne, V., Paradis, V., Pernot, S., Castelnau, C., Vullierme, M.P., Bouattour, M., et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 22 (2010), 1106–1110.
16. Cho, J.Y., Paik, Y.H., Lim, H.Y., Kim, Y.G., Lim, H.K., Min, Y.W., et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int 33 (2013), 950–957.
17. Takeda, H., Nishikawa, H., Osaki, Y., Tsuchiya, K., Joko, K., Ogawa, C., et al. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int 35 (2015), 1581–1589.
18. Lee, S., Kim, B.K., Kim, S.U., Park, S.Y., Kim, J.K., Lee, H.W., et al. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. J Gastroenterol Hepatol 29 (2014), 1463–1469.
19. Yau, T., Tang, V.Y., Yao, T.J., Fan, S.T., Lo, C.M., Poon, R.T., Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146 (2014), 1691–1700 e1693.
20. Adolfsson, J., Steineck, G., Prognostic and treatment-predictive factors-is there a difference?. Prostate Cancer Prostatic Dis 3 (2000), 265–268.
21. Poon, R.T., Cheung, T.T., Kwok, P.C., Lee, A.S., Li, T.W., Loke, K.L., et al. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer 4 (2015), 51–69.
22. Kudo, M., Matsui, O., Izumi, N., Iijima, H., Kadoya, M., Imai, Y., et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 3 (2014), 458–468.
23. Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33 (2015), 550–558.
24. Bronowicki, J.-P., Kudo, M., Lencioni, R., Chen, X.-P., Dagher, L., Furuse, J., et al. Gideon: A retrospective analysis of prognostic factors for survival. J Hepatol 62 (2015), S451–S452.
25. Jackson, R., Psarelli, E.E., Berhane, S., Khan, H., Johnson, P., Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J Clin Oncol 35 (2017), 622–628.
26. Pocock, S.J., Stone, G.W., The primary outcome is positive – Is that good enough?. N Engl J Med 375 (2016), 971–979.
27. Guthrie, G.J., Charles, K.A., Roxburgh, C.S., Horgan, P.G., McMillan, D.C., Clarke, S.J., The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88 (2013), 218–230.
28. Aggarwal, B.B., Vijayalekshmi, R.V., Sung, B., Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15 (2009), 425–430.
29. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
30. O'Callaghan, D.S., O'Donnell, D., O'Connell, F., O'Byrne, K.J., The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 5 (2010), 2024–2036.
31. Templeton, A.J., McNamara, M.G., Seruga, B., Vera-Badillo, F.E., Aneja, P., Ocana, A., et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 106, 2014, dju124.
32. Wang, J., Jia, Y., Wang, N., Zhang, X., Tan, B., Zhang, G., et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med, 12(7), 2014 Available from: https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-12-7.
33. Xiao, W.K., Chen, D., Li, S.Q., Fu, S.J., Peng, B.G., Liang, L.J., Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer, 14, 2014, 117.
34. Xue, T.C., Zhang, L., Xie, X.Y., Ge, N.L., Li, L.X., Zhang, B.H., et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS One, 9, 2014, e96072.
35. Qi, X., Li, J., Deng, H., Li, H., Su, C., Guo, X., Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget 7 (2016), 45283–45301.
36. Casadei Gardini, A., Scarpi, E., Faloppi, L., Scartozzi, M., Silvestris, N., Santini, D., et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget 7 (2016), 67142–67149.
37. Sun, X.D., Shi, X.J., Chen, Y.G., Wang, C.L., Ma, Q., Lv, G.Y., Elevated preoperative neutrophil-lymphocyte ratio is associated with poor prognosis in hepatocellular carcinoma patients treated with liver transplantation: a meta-analysis. Gastroenterol Res Pract, 2016, 2016, 4743808.
38. Reig, M., Torres, F., Rodriguez-Lope, C., Forner, A., LLarch, N., Rimola, J., et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 61 (2014), 318–324.
39. Ogasawara, S., Chiba, T., Ooka, Y., Kanogawa, N., Saito, T., Motoyama, T., et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 33 (2015), 729–739.
40. Clark, T.W., Complications of hepatic chemoembolization. Semin Intervent Radiol 23 (2006), 119–125.
41. Huang, Y.S., Chiang, J.H., Wu, J.C., Chang, F.Y., Lee, S.D., Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 97 (2002), 1223–1227.
42. Chung, J.W., Park, J.H., Han, J.K., Choi, B.I., Han, M.C., Lee, H.S., et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198 (1996), 33–40.
43. Sieghart, W., Hucke, F., Pinter, M., Graziadei, I., Vogel, W., Muller, C., et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57 (2013), 2261–2273.
44. Ribeiro de Souza, A., Reig, M., Bruix, J., Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opin Pharmacother 17 (2016), 1923–1936.
45. Llovet, J.M., Pena, C.E., Lathia, C.D., Shan, M., Meinhardt, G., Bruix, J., et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18 (2012), 2290–2300.
46. Raoul, J.L., Bruix, J., Greten, T.F., Sherman, M., Mazzaferro, V., Hilgard, P., et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 56 (2012), 1080–1088.